Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(1):25–47. doi: 10.1111/j.1527-3458.2001.tb00189.x

Paroxetine: A Review

Michel Bourin 1,2,✉, Pierre Chue 2, Yannick Guillon 1
PMCID: PMC6741642  PMID: 11420571

ABSTRACT

Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive‐compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache.

Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5‐hydroxytryptamine, 5‐HT) of all the currently available antidepressants including the class of SSRIs. It is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs. The selectivity of paroxetine, i.e., the ratio of inhibition of uptake of norepinephrine to serotonin (NE/5‐HT) is amongst the highest of the SSRIs. Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, has a reduced propensity to cause central and autonomic side effects. Paroxetine exhibits some affinity for the muscarinic cholinergic receptor but much less than the TCAs. In addition, the adaptive changes of somatodendritic (5‐HT1A) and terminal (5‐HT1B/1D) autoreceptors observed with paroxetine are different to those observed with TCAs; it also inhibits nitric oxide synthase. It is both a substrate and an inhibitor of cytochrome isoenzyme P450 2D6. Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable. Its metabolites are pharmacologically inactive in vivo. Steady state levels are achieved after 4–14 days and an elimination half‐life of 21 h is consistent with once‐daily dosing. There is wide inter‐individual variation in the pharmacokinetics of paroxetine in adults as well as in the young and the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment. Serious adverse events are, however, extremely rare even in overdose.

In summary, paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range.

Keywords: Anxiety, Depression, Obsessive‐compulsive disorder, Panic disorder, Paroxetine, Serotonin reuptake inhibitors, Social phobia

Full Text

The Full Text of this article is available as a PDF (199.6 KB).

References

  • 1. Albers LJ, Reist C, Helmeste D. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996;59:189–196. [DOI] [PubMed] [Google Scholar]
  • 2. Allgulander C, Cloniger CR, Przybeck TR, Brandt L. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull 1998;34:165–166. [PubMed] [Google Scholar]
  • 3. Anderson IM, Tomenson BM. The efficacy of selective serotonin re‐uptake inhibitors in depression: A meta‐analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238–249. [DOI] [PubMed] [Google Scholar]
  • 4. Ansseau M, Gabriels A, Loyens J, et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharm 1994;9:329–336. [Google Scholar]
  • 5. Armstrong SC, Schweitzer SM. Delirium associated with paroxetine and benztropine combination. Am J Psychiatr 1997;154:581–582. [DOI] [PubMed] [Google Scholar]
  • 6. Baldassano CF, Sachs GS, Stoll A, et al. Paroxetine for bipolar depression: Outcome in patients failing prior antidepressant trials. Depression 1995;3:182–186. [Google Scholar]
  • 7. Baldwin D, Bobes J, Stein D, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. Br J Psychiatry 1999;175:120–126. [DOI] [PubMed] [Google Scholar]
  • 8. Baldwin DS, Hawley CJ, Abed R, et al. A multicenter double‐blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate‐to‐severe depression. J Clin Psychiatry 1996;57 (2): 46–52. [PubMed] [Google Scholar]
  • 9. Ballenger JC, Wheadon DE, Steiner M, et al. Double‐blind, fixed dose, placebo‐controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatr 1998;155:36–42. [DOI] [PubMed] [Google Scholar]
  • 10. Bignamini A, Rapisarda V. A double‐blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Int Clin Psychopharmacol 1992;6 (4): 37–41. [DOI] [PubMed] [Google Scholar]
  • 11. Blier P, de Montigny C, Chaput X. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51 (4): 14–20. [PubMed] [Google Scholar]
  • 12. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521–523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Bolden‐Watson C, Richelson E. Blockade by newly‐developped anti‐depressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52 (12): 1023–1029. [DOI] [PubMed] [Google Scholar]
  • 14. Bourin M, Redrobe JP, Baker GB. Pindolol does not act only on 5‐HT1A receptors in augmenting antide‐pressant activity in the mouse forced swimming test. Psychopharmacology 1998;136 (3): 226–34. [DOI] [PubMed] [Google Scholar]
  • 15. Brett MA, Dierdorf H‐D, Zussman BD, Coates PE. Determination of paroxetine in human plasma, using high‐performance liquid chromatography with fluorescence detection. J Chromatogr 1987;419:438–444. [DOI] [PubMed] [Google Scholar]
  • 16. Broodhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264:2524–2528. [PubMed] [Google Scholar]
  • 17. Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;4:349–55. [DOI] [PubMed] [Google Scholar]
  • 18. Budman CL, Sherling M, Brunn RD. Combined pharmacotherapy risk [letter]. J Am Acad Child Adolesc Psychiatry 1995;34:263–264. [DOI] [PubMed] [Google Scholar]
  • 19. Bump GM, Reynolds CF, Smith G, et al. Accelerating response in geriatric depression: A pilot study combining sleep deprivation and paroxetine. Depress Anxiet 1997;6:113–118. [PubMed] [Google Scholar]
  • 20. Cain CR, Hamilton TC, Norton J, et al. Relative lack of cardiotoxicity of paroxetine in animal models. Acta Psychiatr Scand 1989;80 (Suppl 350): 27–30. [DOI] [PubMed] [Google Scholar]
  • 21. . Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialities 2000. 35th Edition Publishers Webcom Ltd., Toronto . [Google Scholar]
  • 22. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selected serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820–822. [DOI] [PubMed] [Google Scholar]
  • 23. Christiansen PE, Behnke K. Black CH, et al. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996;93:158–163. [DOI] [PubMed] [Google Scholar]
  • 24. Claghorn JL, Feighner JP. A double‐blind comparison of paroxetine with imipramine in the long‐term treatment of depression. J Clin Psychopharmacol 1993;13:23–27. [DOI] [PubMed] [Google Scholar]
  • 25. Claghorn JL, Kiev A, Rickets K. Paroxetine versus placebo: A double‐blind comparison in depressed patients. J Clin Psychiatry 1992;53:434–438. [PubMed] [Google Scholar]
  • 26. Crew HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) in human liver microsomes. Br J Clin Pharmacol 1992;34:262–265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Cryan JF, McGrath C, Leonard BE, Norman TR. Onset of the effects of the 5‐HT1A antagonist, WAY‐100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8‐OH‐DPAT‐induced changes in the rat. Pharmacol Biochem Behav 1999;63(2): 333–8. [DOI] [PubMed] [Google Scholar]
  • 28. De Wilde J, Spiers R, Mertens, et al. A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Hosp Formul 1993;28:36–40. [DOI] [PubMed] [Google Scholar]
  • 29. Dechant KL, Clisshold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225–253. [DOI] [PubMed] [Google Scholar]
  • 30. Dunbar GC. Paroxetine in the elderly: A comparative meta‐analysis against standard antidepressant pharmacotherapy. Pharmacology 1995;51:137–144. [DOI] [PubMed] [Google Scholar]
  • 31. Dunner DL, Cohn JB, Walshe T, et al. Two combined, multicenter double‐blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53 (2): 57–60. [PubMed] [Google Scholar]
  • 32. Dunner DL. Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 1994;55:48–58. [PubMed] [Google Scholar]
  • 33. Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo‐controlled trial of paroxetine versus imipramine in depressed HIV‐positive outpatients. Am J Psychiatr 1998;155:367–372. [DOI] [PubMed] [Google Scholar]
  • 34. Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine, placebo and imipramine in depressed patients. J Affect Disord 1993;28:71–79. [DOI] [PubMed] [Google Scholar]
  • 35. Finkel MS, Laghrissi‐Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653–658. [PubMed] [Google Scholar]
  • 36. Finley PR. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994;28:1359–1369. [DOI] [PubMed] [Google Scholar]
  • 37. Folkerts HW, Michael N, Tolle R, et al. Electroconvulsive therapy vs. paroxetine in treatment‐resistant depression‐a randomized study. Acta Psychiatr Scand 1997;96:334–342. [DOI] [PubMed] [Google Scholar]
  • 38. Foster RH, Goa KL. Paroxetine. A review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs 1997;8:63–188. [DOI] [PubMed] [Google Scholar]
  • 39. Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 1995;119:277–281. [DOI] [PubMed] [Google Scholar]
  • 40. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders — tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12 (3): S55–S87. [DOI] [PubMed] [Google Scholar]
  • 41. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders — efficacy and quality of life. J Psychopharmacol 1998;12 (3): S21–S34. [DOI] [PubMed] [Google Scholar]
  • 42. Grados MA, Labuda MC, Riddle MA and Walkup JT. Obsessive‐compulsive disorder in children and adolescents. Int Rev Psychiatry 1997;9:83–97. [Google Scholar]
  • 43. Grimsley SR, Jann MW. Paroxetine, sertraline and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930–957. [PubMed] [Google Scholar]
  • 44. Guillibert E, Pelicier Y, Archambault JC, et al. A double‐blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80 (Suppl 350): 132–134. [DOI] [PubMed] [Google Scholar]
  • 45. Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55:85–120. [DOI] [PubMed] [Google Scholar]
  • 46. Haddock RE, Johnson AM, Langley PE, et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand 1989;80 (Suppl 350): 24–26. [DOI] [PubMed] [Google Scholar]
  • 47. Hindmarch L Kerr JS. Effects of paroxetine on cognitive function in depressed patients, volunteers and elderly volunteers. Med Sci Res 1994;22:669–670. [Google Scholar]
  • 48. Horrigan JP, Barnhill LJ. Paroxetine‐pimozide drug interaction [letter]. J Am Acad Child Adolesc Psychiatry 1994;33:1060–1061. [DOI] [PubMed] [Google Scholar]
  • 49. Hutchinson DR, Tong S, Moon AL et al. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br J Clin Res 1992;2:43–57. [DOI] [PubMed] [Google Scholar]
  • 50. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1994;9 (1): 19–26. [DOI] [PubMed] [Google Scholar]
  • 51. Ichelson E. Pharmacology of antidepressants. Characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069–1081. [DOI] [PubMed] [Google Scholar]
  • 52. Ieni JR, Meyerson LR. The 5‐HT1A receptor probe [3H]8‐OH‐DPAT labels the 5‐HT transporter human platelets. Life Sci 1988;42:311–320. [DOI] [PubMed] [Google Scholar]
  • 53. Johnson AM. Paroxetine: A pharmacological review. Int Clin Psychopharmacology 1992;6:15–24. [PubMed] [Google Scholar]
  • 54. Kamath M, Finkel SI, Moran MB. A retrospective chart review of antidepressant use effectiveness and adverse effects in adults age 70 and older. Am J Geriatric Psychiatry 1996;4:167–172. [DOI] [PubMed] [Google Scholar]
  • 55. Katona CL, Hunter BN, Bray J. A double‐blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatry Psychiatry 1998;13:100–108. [DOI] [PubMed] [Google Scholar]
  • 56. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;80 (Suppl 350): 60–75. [DOI] [PubMed] [Google Scholar]
  • 57. Keller MB, Lavoir PW, Price J, et al. The persistant risk of chronicity in recurrent episodes of non‐bipolar major depressive disorder: A perspective follow‐up. Am J Psychiatry 1986;143:24–28. [DOI] [PubMed] [Google Scholar]
  • 58. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity and levels of psychopathology in major depression. A 5 year prospective follow up of 431 subjects. Arch Gen Psychiatry 1992;49 (10): 809–816. [DOI] [PubMed] [Google Scholar]
  • 59. Keller MB. Depression: Along term illness. Br J Psychiatry 1994;165 (26): 9–15. [PubMed] [Google Scholar]
  • 60. Kiev A, Feiger A. A double‐blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997;58:146–152. [DOI] [PubMed] [Google Scholar]
  • 61. Kleinlogel H, Burke HR. Effects of the selective 5‐hydroxytryptamine uptake inhibitors paroxetine and zimelidine or EEG sleep and working stages in the rat. Neuropsychobiology 1987;17:206–212. [DOI] [PubMed] [Google Scholar]
  • 62. Koks S, Bourin M, Voikar V, et al. Role of CCK in anti‐exploratory action of paroxetine, 5‐HT reuptake inhibitor. Int J Neuropsychopharm 1999;2:9–16. [DOI] [PubMed] [Google Scholar]
  • 63. Lecrubier Y, Bakker A, Dunbar G and Judge R. A comparison of paroxetine clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145–152. [DOI] [PubMed] [Google Scholar]
  • 64. Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipramine concentration. A report of two cases. Hum Psychopharmacol 1995;10:345–7. [Google Scholar]
  • 65. Lundmark J. Thomsen IS, Fjord‐Larsen T, et al. Paroxetine: Pharmacokinetic and antidepressant effects in the elderly. Acta Psychiatr Scand 1989;80 (Suppl 350): 76–80. [DOI] [PubMed] [Google Scholar]
  • 66. Magnussen I, Tonder K, Engbach F. Paroxetine a potent selective long acting inhibitor of synaptosomal 5‐HT uptake in mice. J Neural Transm 1982;55:217–226. [Google Scholar]
  • 67. Malagié I, Trillat AC, Bourin M, et al. 5‐HT1B autoreceptors limit the effects of selective serotonin reuptake inhibitors in mouse hippocampus and frontal cortex. J Neurochemistry 2001;(in press). [DOI] [PubMed] [Google Scholar]
  • 68. Malek‐Ahmadi P, Allen SA. Paroxetine‐molindone interaction. J Clin Psychiatry 1995;56:82–83. [PubMed] [Google Scholar]
  • 69. Mancini C, Van Ameringen M. Paroxetine in social phobia. J Clin Psychiatry 1996;57:519–522. [DOI] [PubMed] [Google Scholar]
  • 70. Menting JE, Honig A, Verhey FR, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: A qualitative analysis of the literature on their efficacy and side‐effects. Int Clin Psychopharmacol 1996;11:165–175. [DOI] [PubMed] [Google Scholar]
  • 71. Moller H‐J, Berzewski H, Eckmann F, et al. Double‐blind multicentre study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993;26:75–8. [DOI] [PubMed] [Google Scholar]
  • 72. Montgomery SA. Implications of the severity of social phobia. J Affect Disord 1998;50:S17–S22. [DOI] [PubMed] [Google Scholar]
  • 73. Montgomery SA. Long‐term treatment of depression. Br J Psychiatry 1994;165 (Suppl 26): 31–36. [PubMed] [Google Scholar]
  • 74. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189–95. [DOI] [PubMed] [Google Scholar]
  • 75. Morris JB, Back AT. The efficacy of antidepressant drugs: A review of research. Arch Gen Psychiatry 1974;30:667–674. [DOI] [PubMed] [Google Scholar]
  • 76. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive‐compulsive disorder: A single‐blind study. J Clin Psychopharmacol 1997;17:267–270. [DOI] [PubMed] [Google Scholar]
  • 77. Nelson DR, Palmer KJ, Tasker T and Tulloch IF. Neurochemical evidence that the antidepressant paroxetine is a selective serotonin reuptake inhibitor in man. Depression 1993;1:263–267. [Google Scholar]
  • 78. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 1994;14:127–138. [PubMed] [Google Scholar]
  • 79. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double‐blind, placebo‐controlled study. Br J Psychiatry 1995;167:374–379. [DOI] [PubMed] [Google Scholar]
  • 80. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999;60:519–523. [DOI] [PubMed] [Google Scholar]
  • 81. Piccineli M, Wilkinson G. Outcome of depression in psychiatric settings. Br J Psychiatry 1994;164:297–304. [DOI] [PubMed] [Google Scholar]
  • 82. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment‐resistant depression. Double‐blind, randomised comparison. Br J Psychiatry 1999;175:12–16. [DOI] [PubMed] [Google Scholar]
  • 83. Prakash A, Foster RH. Paroxetine. A review of its use in social anxiety disorder. CNS Drugs 1999;12:151–169. [Google Scholar]
  • 84. Rachel H, Goa F, Goa KL. Paroxetine: A review of its pharmacology and therapeutic potential in the management of panic disorder. Drugs 1997;8:163–188. [DOI] [PubMed] [Google Scholar]
  • 85. Raptopoulos P, MacClelland GR, Jackson D. The clinical pharmacology of paroxetine in healthy subjects. Acta Psychiatr Scand 1989;80 (Suppl 350): 46–48. [DOI] [PubMed] [Google Scholar]
  • 86. Ravindran AV, Judge R, Hunter BN, et al. A double‐blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 1997;58:112–118. [DOI] [PubMed] [Google Scholar]
  • 87. Redrobe JP, Bourin M, Colombel MC and Baker GB. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: Implication of noradrenergic and serotonergic mechanisms. J Psychopharmacology 1998;12:348–355. [DOI] [PubMed] [Google Scholar]
  • 88. Redrobe JP, Bourin M. Clonidine potentiates the effects of 5‐HT1A, 5‐HT1B and 5‐HT2A/2C antagonists and 8‐OH‐DPAT in the mouse forced swimming test. Eur Neuropsychopharmacol 1998;8 (3): 169–73. [DOI] [PubMed] [Google Scholar]
  • 89. Richelson E. Pharmacology of anti‐depressants — characteristics of the ideal drug. Mayo Clin Proc 1999;69:1069–1081. [DOI] [PubMed] [Google Scholar]
  • 90. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55:34–41. [PubMed] [Google Scholar]
  • 91. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444–450. [DOI] [PubMed] [Google Scholar]
  • 92. Roose SP, Laghrissi‐Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287–291. [DOI] [PubMed] [Google Scholar]
  • 93. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467–489. [DOI] [PubMed] [Google Scholar]
  • 94. Schlosser R, Wetzel H, Dorr H, et al. Effects of subchronic paroxetine administration on night‐time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 2000;25:377–388. [DOI] [PubMed] [Google Scholar]
  • 95. Schnyder U, Koller‐Leiser A. A double blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 1996;41:239–244. [DOI] [PubMed] [Google Scholar]
  • 96. Schnyder U. Sudden recovery from depression under treatment with paroxetine. Eur J Psychiatry 1996;10:184–187. [Google Scholar]
  • 97. Shone W, Ludwig M. A double blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993;13:34S–39S. [DOI] [PubMed] [Google Scholar]
  • 98. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288–95. [DOI] [PubMed] [Google Scholar]
  • 99. Staner L, Kerkhofs M, Detroux D, et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitiptyline: A double‐blind randomized trial in major depression. Sleep 1995;18:470–477. [PubMed] [Google Scholar]
  • 100. Stein DJ, Berk M, Els C, et al. A double‐blind placebo‐controlled trial of paroxetine in management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999;89:402–406. [PubMed] [Google Scholar]
  • 101. Stein MB, Chartier MJ, Hazen RN, et al. Paroxetine in the treatment of generalized social phobia: Openlabel treatment and double‐blind placebo‐controlled discontinuation. J Clin Psychopharmacol 1996;16:218–222. [DOI] [PubMed] [Google Scholar]
  • 102. Stowe Z, Cohen L, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157 (2): 185–189. [DOI] [PubMed] [Google Scholar]
  • 103. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicentre double‐blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241–6. [PubMed] [Google Scholar]
  • 104. Szegedi A, Wetzel H, Angersbach D, et al. A double‐blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997;30:97–105. [DOI] [PubMed] [Google Scholar]
  • 105. Szegedi A, Wetzel H, Angersbach D, et al. Response to treatment in minor and major depression: Results of a double‐blind comparative study with paroxetine and maprotiline. J Affect Disord 1997;45:167–178. [DOI] [PubMed] [Google Scholar]
  • 106. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5‐hydroxytryptamine uptake inhibitor. Psychopharmacology 1987;98:193–200. [DOI] [PubMed] [Google Scholar]
  • 107. Tignol J. A double‐blind, randomized, fluoxetine‐controlled multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993;13 (2): 18–22. [DOI] [PubMed] [Google Scholar]
  • 108. Tulloch IF, Johnson AM. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;53:7–12. [PubMed] [Google Scholar]
  • 109. Wolfersdorf M, Barg T, Konig F, et al. Paroxetine as antidepressant in combined antidepressant‐neuroleptic therapy in delusional depression: Observation of clinical use. Pharmacopsychiatry 1995;28:56–60. [DOI] [PubMed] [Google Scholar]
  • 110. Wong DT, Bymaster FP. Development of antidepressant drugs In: Tang L. & Tang S, Eds. Neurochemistry in Clinical Application. New York : Plenum Press, 1995. [Google Scholar]
  • 111. Yeragani VK, Jampala VC, Sobelewski E, et al. Effects of paroxetine on heart period variability in patients with panic disorder: A study of Holter ECG records. Neuropsychobiology 1999;40:124–128. [DOI] [PubMed] [Google Scholar]
  • 112. Yokota S, Iskikura Y, Omo H. Cardiovascular effects of paroxetine, a newly developed antidepressant in anaesthetized dogs, in comparison with those of imipramine, amitriptyline and clomipramine. Jpn J Pharmacol 1987;46:335–342. [DOI] [PubMed] [Google Scholar]
  • 113. Zanardi R, Franchini L, Gasperini M. Double‐blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153:1631–3. [DOI] [PubMed] [Google Scholar]
  • 114. Zaninelli R, Meister W. The treatment of depression with paroxetine in psychiatric practice in Germany: The possibilities and current limitations of drug monitoring. Pharmacopsychiatry 1997;30:9–20. [DOI] [PubMed] [Google Scholar]
  • 115. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive‐compulsive disorder. Br J Psychiatry 1996;169:468–474. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES